Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Before the recruitment of patients, the study was approved by Brazil Platform (a national and unified basis of research involving human subjects records) and published by the ClinicalTrials.gov~Inclusion Criteria:~* ASA I or II~* BMI between 18 and 29~Exclusion Criteria:~* Use of medications that could affect the neuromuscular blockade such as calcium channel inhibitors, anticonvulsants and lithium carbonate~* Presence of neuromuscular, renal or hepatic dysfunction.~* Hypermetabolic or hypometabolic states such as fever, infection, and hyperthyroidism or hypothyroidism~* Acid-base disorder, congestive heart failure or conductive heart problems, and those who were being treated for cardiac arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group M (Type: EXPERIMENTAL): Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds.
- Group ML (Type: EXPERIMENTAL): Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds
- Group C (Type: PLACEBO_COMPARATOR): Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds

Based on this trial design, predict the completion outcome and termination type (if applicable).